Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Sep 15:3:34.
doi: 10.1186/1479-5876-3-34.

Immunologic aspect of ovarian cancer and p53 as tumor antigen

H W Nijman  1 , A Lambeck, S H van der Burg, A G J van der Zee, T Daemen
Affiliations

Immunologic aspect of ovarian cancer and p53 as tumor antigen

H W Nijman et al. J Transl Med. .

Abstract

Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease.

PubMed Disclaimer

References

    1. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001;82:435–441. doi: 10.1006/gyno.2001.6313. - DOI - PubMed
    1. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974–979. - PubMed
    1. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–108. doi: 10.1006/gyno.1998.4955. - DOI - PubMed
    1. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998;25:340–348. - PubMed
    1. Thigpen JT. Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol. 2000;27:11–16. - PubMed